Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company targeting drug resistance in cancer, has been awarded the 2026 Biotech Breakthrough Award for Cancer Immunology Solution of the Year for its investigational therapy ENV-105 (carotuximab). The recognition highlights the company's approach to restoring and extending the effectiveness of existing cancer treatments in metastatic prostate cancer and non-small cell lung cancer, areas where resistance to standard therapies remains a major clinical challenge.
ENV-105 is an investigational neutralizing antibody being evaluated in combination with standard-of-care therapies. The award follows recently reported positive interim efficacy data from Kairos Pharma's ongoing Phase 2 trial of ENV-105 combined with apalutamide in patients with metastatic castration-resistant prostate cancer. The interim analysis demonstrated a statistically significant difference in progression-free survival between patients receiving the combination therapy and those receiving apalutamide alone, suggesting a potential breakthrough in addressing drug resistance.
The significance of this award lies in its validation of Kairos Pharma's structural biology approach to oncology. By targeting CD105—a protein identified as a key driver of resistance and disease relapse—ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. This mechanism could offer a new therapeutic strategy for patients whose cancers have become refractory to conventional treatments, potentially improving outcomes in hard-to-treat populations.
For investors, the recognition may enhance the company's visibility and credibility in the competitive biotech landscape. Kairos Pharma is listed on the NYSE American under the ticker KAPA, and the award comes at a time when the company is advancing its lead candidate through clinical development. The positive interim data and the award together could signal progress toward potential regulatory milestones and partnership opportunities. More information about Kairos Pharma is available through its newsroom.
The announcement was disseminated by BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and editorial syndication to 5,000+ outlets, among other services. Such distribution networks help emerging biotech companies reach a broad audience of investors and industry stakeholders, amplifying the impact of announcements like this award.
While the award itself does not guarantee clinical success, it draws attention to the unmet need in cancer immunology and the potential of combination therapies to overcome resistance. For patients with metastatic prostate or lung cancer, new options are urgently needed, and Kairos Pharma's progress will be closely watched as the Phase 2 trial continues. The company's ability to leverage structural biology to design therapies that target resistance mechanisms could set a precedent for future drug development in oncology.
